Cargando…
Role of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence
Cerebral edema and contusion expansion are major determinants of morbidity and mortality after TBI. Current treatment options are reactive, suboptimal and associated with significant side effects. First discovered in models of focal cerebral ischemia, there is increasing evidence that the sulfonylur...
Autores principales: | Jha, Ruchira M., Bell, Josh, Citerio, Giuseppe, Hemphill, J. Claude, Kimberly, W. Taylor, Narayan, Raj K., Sahuquillo, Juan, Sheth, Kevin N., Simard, J. Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013742/ https://www.ncbi.nlm.nih.gov/pubmed/31936452 http://dx.doi.org/10.3390/ijms21020409 |
Ejemplares similares
-
Sulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Review
por: Jha, Ruchira M., et al.
Publicado: (2021) -
Glibenclamide for Brain Contusions: Contextualizing a Promising Clinical Trial Design that Leverages an Imaging-Based TBI Endotype
por: Jha, Ruchira M., et al.
Publicado: (2023) -
Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide
por: Irvine, Hannah J., et al.
Publicado: (2022) -
Precision Effects of Glibenclamide on MRI Endophenotypes in Clinically Relevant Murine Traumatic Brain Injury
por: Zusman, Benjamin E., et al.
Publicado: (2022) -
Management of sulfonylurea‐treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer
por: Shepherd, M., et al.
Publicado: (2017)